Clinical trial
A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
NCT03184870 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 8, 2017
- Completion date
- June 14, 2023
- Enrollment
- 332 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.
colorectal cancer, pancreatic cancer